OneMedNet Reports Significant Expansion of iRWD Network and Platform for Real World Data
MINNEAPOLIS, May 23, 2024 - OneMedNet Corporation (Nasdaq: ONMD), a leading curator of regulatory-grade Real World Data (RWD), has announced a remarkable expansion of its proprietary iRWD network and platform. This development marks a greater than five-fold increase in capabilities, further strengthening the company’s position in the field.
OneMedNet has played a crucial role in gathering and organizing electronic health records, laboratory results, and medical imaging data to create a comprehensive and reliable resource for researchers, clinicians, and life science innovators. By providing regulatory-grade RWD, the company has enabled breakthroughs in pharmaceutical research, clinical trials, and healthcare delivery.
The newly expanded iRWD network and platform will undoubtedly enhance OneMedNet’s ability to cater to the growing demand for real-world evidence in the field of women’s health. Just a few months ago, the company had stated its intention to focus on this area and had already seen promising developments.
With increasing interest from leading pharmaceutical companies, OneMedNet aims to support their research initiatives by providing them with the necessary RWD for women’s health programs. The company has already received multiple orders, indicating a strong demand for its services and affirming its position as a trusted partner in life science research.
By curating high-quality imaging Real World Data, OneMedNet is contributing to advancements in the understanding and treatment of various women’s health conditions. This expansion of their iRWD network and platform not only reinforces their commitment to this important field but also demonstrates their continuous effort to stay ahead of technological advancements.
According to industry experts, the availability of real-world evidence is crucial to improving the development and regulatory approval of new medicines, especially in sensitive areas such as women’s health. OneMedNet’s expanded iRWD network will support research efforts in areas such as breast cancer, gynecological disorders, fertility treatments, and maternal health, among others.
The company’s ongoing commitment to providing regulatory-grade RWD means that researchers and clinicians can now access a wealth of data to analyze, validate, and improve healthcare practices specific to women’s health. The expanded iRWD network is expected to provide an even more comprehensive and diverse dataset, benefiting the entire healthcare ecosystem.
In summary, OneMedNet’s recent expansion of its iRWD network and platform serves as a testament to the increasing demand for real-world evidence in the field of women’s health. The company’s commitment to curating high-quality RWD and staying ahead of technological advancements positions them as a trusted partner for leading pharmaceutical companies and life science innovators. The continued growth of their iRWD network will undoubtedly contribute to advancements in research, clinical trials, and ultimately, improved healthcare outcomes for women worldwide.
Comments